March 11, 2019
Keio University Hospital
The Cancer Center at Keio University Hospital has been conducting the "PleSSision Test," a gene panel test that examines 160 cancer genes through commissioned analysis, to provide each patient with information on the most suitable cancer therapeutic drugs. This test is not covered by health insurance and is paid for out-of-pocket by the patient.
To further promote cancer genomic medicine, we have now introduced the "PleSSision-Exome Test," which analyzes approximately 20,000 genes, corresponding to nearly all human genes. This test is not covered by health insurance, and the full cost must be borne by the patient. It is expected that this test will detect cancer gene abnormalities with higher precision than conventional methods and effectively provide treatment-related information.
At Keio University Hospital, in addition to the "PleSSision-Rapid Test" screening (currently conducted as a clinical study) and the "PleSSision Test" gene panel test, which has already been used in over 500 cases, we have introduced the state-of-the-art, high-precision "PleSSision-Exome Test." This has established a system to broadly promote cancer genomic medicine. We aim to implement these tests in routine clinical practice to provide cancer genomic medicine to as many patients as possible in the future.
Please see below for the full press release.